Bravecto

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

fluralaner

Available from:

Intervet International B.V

ATC code:

QP53BE02

INN (International Name):

fluralaner

Therapeutic group:

Dogs; Cats

Therapeutic area:

Ectoparasiticides za sistemsku primjenu, Изоксазолинов

Therapeutic indications:

Psi:- za liječenje krpelja i buha infestacije;proizvod se može koristiti kao dio strategije tretmana za kontrolu buha dermatitis alergije (FAD). - Za liječenje demodectic šuge, uzrokovane демодекс канис;- za liječenje саркоптозом (Sarcoptes bolesti VDP. канис) infekcija. - For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus. [chewable tablets only]Cats:- For the treatment of tick and flea infestations;The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). - Za liječenje gljivica iz uha kliještima (Otodectes cynotis).

Product summary:

Revision: 17

Authorization status:

odobren

Authorization date:

2014-02-11

Patient Information leaflet

                                40
B. UPUTA O VMP
41
UPUTA O VMP:
BRAVECTO 112,5 MG TABLETE ZA ŽVAKANJE ZA VRLO MALE PSE (2-4,5 KG)
BRAVECTO 250 MG TABLETE ZA ŽVAKANJE ZA MALE PSE (>4,5 -10 KG)
BRAVECTO 500 MG TABLETE ZA ŽVAKANJE ZA SREDNJE VELIKE PSE (>10-20 KG)
BRAVECTO 1000 MG TABLETE ZA ŽVAKANJE ZA VELIKE PSE (>20-40 KG)
BRAVECTO 1400 MG TABLETE ZA ŽVAKANJE ZA VRLO VELIKE PSE (>40-56 KG)
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Nizozemska
Proizvođač odgovoran za puštanje serije u promet:
Intervet GesmbH
Siemensstrasse 107
1210 Beč
Austrija
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg)
Bravecto 250 mg tablete za žvakanje za male pse (>4,5 -10 kg)
Bravecto 500 mg tablete za žvakanje za srednje velike pse (>10-20 kg)
Bravecto 1000 mg tablete za žvakanje za velike pse (>20-40 kg)
Bravecto 1400 mg tablete za žvakanje za vrlo velike pse (>40-56 kg)
fluralaner
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Svaka Bravecto tableta za žvakanje sadrži:
BRAVECTO TABLETE ZA ŽVAKANJE
FLURALANER (MG)
za vrlo male pse (2 - 4,5 kg)
112,5
za male pse (>4,5 - 10 kg)
250
za pse srednje velike pse (>10 - 20 kg)
500
za velike pse (>20 - 40 kg)
1000
za vrlo velike pse (>40 - 56 kg)
1400
Tableta svijetlo do tamno smeđe boje glatke ili neznatno grube
površine i okruglog oblika. Može se
uočiti poneka pjega ili mrlja.
4.
INDIKACIJE
Za liječenje infestacije pasa krpeljima i buhama.
Ovaj veterinarsko – medicinski proizvod je sustavni insekticid i
akaricid koji:
-
trenutno i kontinuirano ubija buhe (
_Ctenocephalides felis_
) tijekom 12 tjedana,
42
-
trenutno i kontinuirano ubija krpelje tijekom 12 tjedana (
_Ixodes ricinus, Dermacentor _
_reticulatus _
i
_ Dermacentor variablis_
),
-
trenutno i kontinuirano ubija krpelje tijekom 8
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2 - 4,5 kg)
Bravecto 250 mg tablete za žvakanje za male pse (>4,5 - 10 kg)
Bravecto 500 mg tablete za žvakanje za srednje velike pse (>10 - 20
kg)
Bravecto 1000 mg tablete za žvakanje za velike pse (>20 - 40 kg)
Bravecto 1400 mg tablete za žvakanje za vrlo velike pse (>40 - 56 kg)
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
DJELATNA TVAR
Svaka tableta za žvakanje sadrži:
BRAVECTO TABLETE ZA ŽVAKANJE
FLURALANER (MG)
za vrlo male pse (2 - 4,5 kg)
112,5
za male pse (>4,5 - 10 kg)
250
za srednje velike pse (>10 - 20 kg)
500
za velike pse (>20 - 40 kg)
1000
za vrlo velike pse (>40 - 56 kg)
1400
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Tablete za žvakanje.
Tableta svijetlo do tamno smeđe boje glatke ili neznatno grube
površine i okruglog oblika.
Poneka mrlja ili pjega mogu biti uočljive.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Psi
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za liječenje infestacije pasa krpeljima i buhama.
Ovaj veterinarsko – medicinski proizvod je sustavni insekticid i
akaricid koji omogućuje:
-
trenutno i kontinuirano ubijanje buha (
_Ctenocephalides felis_
) tijekom 12 tjedana,
-
trenutno i kontinuirano ubijanje krpelja tijekom 12 tjedana za
_Ixodes ricinus, Dermacentor _
_reticulatus _
i
_ Dermacentor variablis_
,
-
trenutno i kontinuirano ubijanje krpelja 8 tjedana za
_Rhipicephalus sanguineus_
.
Krpelji i buhe moraju se prihvatiti na domaćina i započeti hranjenje
kako bi mogli biti izloženi
djelatnoj tvari.
Proizvod se može koristiti kao dio strategije liječenja u kontroli
alergijskog dermatitisa uzrokovanog
buhama (FAD).
Proizvod se koristi za liječenje demodikoze uzrokovane nametnikom
_Demodex canis. _
Proizvod se koristi za liječenje sarkoptes šuge
_(Sarcoptes scabiei _
var.
_ canis)_
infestacije.
3
Za smanjenje rizika od infekcije
_Babesia canis canis_
putem prijenosa preko
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-03-2022
Public Assessment Report Public Assessment Report Bulgarian 21-03-2022
Patient Information leaflet Patient Information leaflet Spanish 21-03-2022
Public Assessment Report Public Assessment Report Spanish 21-03-2022
Patient Information leaflet Patient Information leaflet Czech 21-03-2022
Public Assessment Report Public Assessment Report Czech 21-03-2022
Patient Information leaflet Patient Information leaflet Danish 21-03-2022
Public Assessment Report Public Assessment Report Danish 21-03-2022
Patient Information leaflet Patient Information leaflet German 21-03-2022
Public Assessment Report Public Assessment Report German 21-03-2022
Patient Information leaflet Patient Information leaflet Estonian 21-03-2022
Public Assessment Report Public Assessment Report Estonian 21-03-2022
Patient Information leaflet Patient Information leaflet Greek 21-03-2022
Public Assessment Report Public Assessment Report Greek 21-03-2022
Patient Information leaflet Patient Information leaflet English 21-03-2022
Public Assessment Report Public Assessment Report English 21-03-2022
Patient Information leaflet Patient Information leaflet French 21-03-2022
Public Assessment Report Public Assessment Report French 21-03-2022
Patient Information leaflet Patient Information leaflet Italian 21-03-2022
Public Assessment Report Public Assessment Report Italian 21-03-2022
Patient Information leaflet Patient Information leaflet Latvian 21-03-2022
Public Assessment Report Public Assessment Report Latvian 21-03-2022
Patient Information leaflet Patient Information leaflet Lithuanian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-03-2022
Public Assessment Report Public Assessment Report Lithuanian 21-03-2022
Patient Information leaflet Patient Information leaflet Hungarian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 21-03-2022
Public Assessment Report Public Assessment Report Hungarian 21-03-2022
Patient Information leaflet Patient Information leaflet Maltese 21-03-2022
Public Assessment Report Public Assessment Report Maltese 21-03-2022
Patient Information leaflet Patient Information leaflet Dutch 21-03-2022
Public Assessment Report Public Assessment Report Dutch 21-03-2022
Patient Information leaflet Patient Information leaflet Polish 21-03-2022
Public Assessment Report Public Assessment Report Polish 21-03-2022
Patient Information leaflet Patient Information leaflet Portuguese 21-03-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 21-03-2022
Public Assessment Report Public Assessment Report Portuguese 21-03-2022
Patient Information leaflet Patient Information leaflet Romanian 21-03-2022
Public Assessment Report Public Assessment Report Romanian 21-03-2022
Patient Information leaflet Patient Information leaflet Slovak 21-03-2022
Public Assessment Report Public Assessment Report Slovak 21-03-2022
Patient Information leaflet Patient Information leaflet Slovenian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 21-03-2022
Public Assessment Report Public Assessment Report Slovenian 21-03-2022
Patient Information leaflet Patient Information leaflet Finnish 21-03-2022
Public Assessment Report Public Assessment Report Finnish 21-03-2022
Patient Information leaflet Patient Information leaflet Swedish 21-03-2022
Public Assessment Report Public Assessment Report Swedish 21-03-2022
Patient Information leaflet Patient Information leaflet Norwegian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 21-03-2022
Patient Information leaflet Patient Information leaflet Icelandic 21-03-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 21-03-2022

Search alerts related to this product

View documents history